-
Signature
-
/s/ Lindsey Rolfe
-
Stock symbol
-
CLVS
-
Transactions as of
-
Aug 1, 2022
-
Transactions value $
-
-$6,326
-
Form type
-
4
-
Date filed
-
8/3/2022, 04:15 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
CLVS |
Common Stock |
Options Exercise |
|
+3.75K |
+3.64% |
|
107K |
Aug 1, 2022 |
Direct |
F1 |
transaction |
CLVS |
Common Stock |
Sale |
-$2.83K |
-1.94K |
-1.82% |
$1.46* |
105K |
Aug 2, 2022 |
Direct |
F2, F3 |
transaction |
CLVS |
Common Stock |
Options Exercise |
|
+4.63K |
+4.41% |
|
109K |
Aug 1, 2022 |
Direct |
F1 |
transaction |
CLVS |
Common Stock |
Sale |
-$3.49K |
-2.39K |
-2.18% |
$1.46* |
107K |
Aug 2, 2022 |
Direct |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
CLVS |
Restricted Stock Units |
Options Exercise |
$0 |
-3.75K |
-33.33% |
$0.00 |
7.5K |
Aug 1, 2022 |
Common Stock |
3.75K |
|
Direct |
F1, F4 |
transaction |
CLVS |
Restricted Stock Units |
Options Exercise |
$0 |
-4.63K |
-14.29% |
$0.00 |
27.8K |
Aug 1, 2022 |
Common Stock |
4.63K |
|
Direct |
F1, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance